| Code | Display |
| 392611000210105 |
BR Metastatic - cARBOplatin [2 AUC] and gemcitabine |
| 392601000210108 |
BR Metastatic - ribociclib |
| 392591000210103 |
LEU - GMALL T-LBL 1/2004 HDMTX/ASP [55 years and under] |
| 392581000210100 |
LEU - GMALL T-LBL 1/2004 Consolidation [55 years and under] |
| 392571000210102 |
LEU - GMALL T-LBL 1/2004 Pre-phase and Induction [55 years and under] |
| 392561000210108 |
LEU ALL precursor T-cell - GMALL T-LBL 1/2004 [55 years and under] |
| 392551000210105 |
LEU - GMALL T-LBL 1/2004 triple prophylaxis |
| 392541000210107 |
LEU - GMALL T-LBL 1/2004 CYCLO/ARAC |
| 392531000210104 |
LEU - GMALL T-LBL 1/2004 VM26/ARAC |
| 392521000210101 |
LEU - GMALL T-LBL 1/2004 Reinduction |
| 392511000210106 |
LEU - GMALL T-LBL 1/2004 HDMTX/ASP [over 55 years] |
| 392501000210109 |
LEU - GMALL T-LBL 1/2004 Consolidation I [over 55 years] |
| 392491000210104 |
LEU - GMALL T-LBL 1/2004 Pre-phase and Induction [over 55 years] |
| 392481000210101 |
LEU ALL precursor T-cell - GMALL T-LBL 1/2004 [over 55 years] |
| 392471000210103 |
LEU - HyperCVAD with pegaspargase [under 40 years] Part B with Intrathecal CNS prophylaxis High Risk |
| 392461000210109 |
LEU - HyperCVAD with pegaspargase [under 40 years] Part B with Intrathecal CNS prophylaxis Unknown Risk [default] |
| 392451000210106 |
LEU - HyperCVAD with pegaspargase [under 40 years] Part A with Intrathecal CNS prophylaxis High Risk |
| 392441000210108 |
LEU - HyperCVAD with pegaspargase [under 40 years] Part A with Intrathecal CNS prophylaxis Unknown Risk [default] |
| 392431000210100 |
LEU ALL - HyperCVAD with pegaspargase Part A and B followed by POMP Maintenance [under 40 years] |
| 392421000210102 |
LEU - UKALL14 with RITUximab [over 40 years] [not for transplant] Consolidation/delayed intensification [Cycle 3] |
| 392411000210107 |
LEU - UKALL14 with RITUximab [over 40 years] [not for transplant] Intensification/CNS prophylaxis |
| 392401000210105 |
LEU ALL precursor B-cell - UKALL14 with RITUximab [over 40 years] [not for transplant] |
| 392391000210107 |
LEU - UKALL14 with RITUximab [not for transplant] Maintenance |
| 392381000210105 |
LEU - UKALL14 with RITUximab [40 years and under] [not for transplant] Consolidation/delayed intensification [Cycle 3] |
| 392371000210108 |
LEU - UKALL14 with RITUximab [40 years and under] [not for transplant] Intensification/CNS prophylaxis |
| 392361000210102 |
LEU - UKALL14 with RITUximab [not for transplant] Phase 2 Induction |
| 392351000210100 |
LEU ALL precursor B-cell - UKALL14 with RITUximab [40 years and under] [not for transplant] |
| 392341000210103 |
LEU - HyperCVAD with RITUximab [60 years and under] Part B with Intrathecal CNS prophylaxis High Risk |
| 392331000210106 |
LEU - HyperCVAD with RITUximab [60 years and under] Part B with Intrathecal CNS prophylaxis Unknown Risk [default] |
| 392321000210109 |
LEU - HyperCVAD with RITUximab [60 years and under] Part A with Intrathecal CNS prophylaxis High Risk |
| 392311000210104 |
LEU - HyperCVAD with RITUximab [60 years and under] Part A with Intrathecal CNS prophylaxis Unknown Risk [default] |
| 392301000210101 |
LEU ALL precursor B-cell - HyperCVAD with RITUximab Part A and B followed by POMP Maintenance [60 years and under] |
| 392291000210100 |
LEU - HyperCVAD with RITUximab [over 60 years] Part B with Intrathecal CNS prophylaxis High Risk |
| 392281000210102 |
LEU - HyperCVAD Part B with RITUximab [over 60 years] Intrathecal CNS prophylaxis Unknown Risk [default] |
| 391941000210106 |
LEU - HyperCVAD Part A with RITUximab [over 60 years] Intrathecal CNS prophylaxis High Risk |
| 391931000210103 |
LEU - HyperCVAD Part A with RITUximab [over 60 years] Intrathecal CNS prophylaxis Unknown Risk [default] |
| 391921000210100 |
LEU ALL precursor B-cell - HyperCVAD with RITUximab Part A and B followed by POMP Maintenance [over 60 years] |
| 391911000210105 |
LEU - UKALL14 with RITUximab [40 years and under] [for transplant] Consolidation/delayed intensification [Cycle 3] |
| 391901000210108 |
LEU - UKALL14 with RITUximab [40 years and under] Consolidation [Cycle 1 and 2] |
| 391891000210107 |
LEU - UKALL14 with RITUximab [40 years and under] [for transplant] Intensification/CNS prophylaxis |
| 391881000210105 |
LEU - UKALL14 with RITUximab [40 years and under] Phase 1 Induction |
| 391871000210108 |
LEU ALL precursor B-cell - UKALL14 with RITUximab [40 years and under] [for transplant] |
| 391861000210102 |
LEU - UKALL14 Consolidation/delayed intensification [Cycle 3] [40 years and under] |
| 391851000210100 |
LEU - UKALL14 Consolidation [Cycle 1] [40 years and under] |
| 391841000210103 |
LEU - UKALL14 Intensification/CNS prophylaxis [40 years and under] |
| 391831000210106 |
LEU - UKALL14 Phase 1 Induction [40 years and under] |
| 391821000210109 |
LEU ALL - UKALL14 [40 years and under] |
| 391811000210104 |
LEU - UKALL14 with RITUximab Consolidation [Cycle 4] |
| 391801000210101 |
LEU - UKALL14 with RITUximab [over 40 years] [for transplant] Consolidation/delayed intensification [Cycle 3] |
| 391791000210100 |
LEU - UKALL14 with RITUximab [over 40 years] Consolidation [Cycle 1 and 2] |
| 391781000210102 |
LEU - UKALL14 with RITUximab [over 40 years] [for transplant] Intensification/CNS prophylaxis |
| 391771000210104 |
LEU - UKALL14 with RITUximab [for transplant] Phase 2 Induction |
| 391761000210105 |
LEU - UKALL14 with RITUximab [over 40 years] Phase 1 Induction |
| 391751000210107 |
LEU ALL precursor B-cell - UKALL14 with RITUximab [over 40 years] [for transplant] |
| 391741000210109 |
LEU - AIDA consolidation 3 [over 70 years] |
| 391731000210101 |
LEU - AIDA consolidation 2 [over 70 years] |
| 391721000210103 |
LEU - AIDA consolidation 1 [over 70 years] |
| 391711000210108 |
LEU - AIDA induction [over 70 years] |
| 391701000210106 |
LEU APL - AIDA induction and consolidations 1, 2 and 3 [over 70 years] |
| 391691000210106 |
LEU AML - DA+GO-1 [DAUNOrubicin, cytarabine and Mylotarg [gemtuzumab ozogamicin]] induction [de novo CD33+] [good or intermediate risk] |
| 391681000210109 |
LEU - Pethema LPA2005 maintenance [70 years and under] [low risk] |
| 391671000210107 |
LEU - Pethema LPA2005 consolidation 3 [70 years and under] [low risk] |
| 391661000210101 |
LEU - Pethema LPA2005 consolidation 2 [70 years and under] [low risk] |
| 391621000210108 |
LEU - Pethema LPA2005 consolidation 1 [70 years and under] [low risk] |
| 391601000210100 |
LEU - Pethema LPA2005 induction [70 years and under] [low risk] |
| 391591000210105 |
LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [70 years and under] [low risk] |
| 391581000210108 |
LEU - Pethema LPA2005 maintenance [over 70 years] [low risk] |
| 391571000210106 |
LEU - Pethema LPA2005 consolidation 3 [over 70 years] [low risk] |
| 391561000210100 |
LEU - Pethema LPA2005 consolidation 2 [over 70 years] [low risk] |
| 391551000210103 |
LEU - Pethema LPA2005 consolidation 1 [over 70 years] [low risk] |
| 391541000210101 |
LEU - Pethema LPA2005 induction [over 70 years] [low risk] |
| 391531000210109 |
LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [over 70 years] [low risk] |
| 391521000210107 |
LEU - Pethema LPA2005 maintenance [over 70 years] [high risk] |
| 391511000210102 |
LEU - Pethema LPA2005 consolidation 3 [over 70 years] [high risk] |
| 391501000210104 |
LEU - Pethema LPA2005 consolidation 2 [over 70 years] [high risk] |
| 391491000210109 |
LEU - Pethema LPA2005 consolidation 1 [over 70 years] [high risk] |
| 391481000210107 |
LEU - Pethema LPA2005 induction [over 70 years] [high risk] |
| 391471000210105 |
LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [over 70 years] [high risk] |
| 391461000210104 |
GU GCT Seminoma Adjuvant - cARBOplatin [7 AUC] |
| 391451000210102 |
GU URO Advanced - cISplatin and gemcitabine |
| 391441000210100 |
GU URO Advanced - cISplatin [split dose] and gemcitabine |
| 391431000210108 |
GU Upper Tract Urothelial Adjuvant - cISplatin [split dose] and gemcitabine |
| 391421000210106 |
GU GCT Metastatic - TIP [PACLItaxel, IFOSFamide and cISplatin] |
| 391411000210101 |
LEU - Pethema LPA2005 maintenance [over 70 years] [intermediate risk] |
| 312741000210103 |
LEU - Pethema LPA2005 consolidation 3 [over 70 years] [intermediate risk] |
| 312731000210106 |
LEU - Pethema LPA2005 consolidation 2 [over 70 years] [intermediate risk] |
| 312721000210109 |
LEU - Pethema LPA2005 consolidation 1 [over 70 years] [intermediate risk] |
| 312711000210104 |
LEU - Pethema LPA2005 induction [over 70 years] [intermediate risk] |
| 312701000210101 |
LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [over 70 years] [intermediate risk] |
| 312691000210101 |
LEU - Pethema LPA2005 maintenance [under 60 years] [high risk] |
| 312681000210103 |
LEU - Pethema LPA2005 consolidation 3 [under 60 years] [high risk] |
| 312671000210100 |
LEU - Pethema LPA2005 consolidation 2 [under 60 years] [high risk] |
| 312661000210106 |
LEU - Pethema LPA2005 consolidation 1 [under 60 years] [high risk] |
| 312651000210108 |
LEU - Pethema LPA2005 induction [under 60 years] [high risk] |
| 312631000210102 |
LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [under 60 years] [high risk] |
| 312621000210104 |
LEU - Pethema LPA2005 maintenance [60 to 70 years] [high risk] |
| 312611000210109 |
LEU - Pethema LPA2005 consolidation 3 [60 to 70 years] [high risk] |
| 312601000210107 |
LEU - Pethema LPA2005 consolidation 2 [60 to 70 years] [high risk] |
| 312591000210102 |
LEU - Pethema LPA2005 consolidation 1 [60 to 70 years] [high risk] |
| 312581000210104 |
LEU - Pethema LPA2005 induction [60 to 70 years] [high risk] |
| 312571000210101 |
LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [60 to 70 years] [high risk] |
| 312561000210107 |
LEU - UKALL14 Maintenance |
| 312551000210109 |
LEU - UKALL14 Consolidation [Cycle 4] |
| 312541000210106 |
LEU - UKALL14 Consolidation/delayed intensification [Cycle 3] [over 40 years] |
| 312531000210103 |
LEU - UKALL14 Consolidation [Cycle 2] |
| 312521000210100 |
LEU - UKALL14 Consolidation [Cycle 1] [over 40 years] |
| 312511000210105 |
LEU - UKALL14 Intensification/CNS prophylaxis [over 40 years] |
| 312501000210108 |
LEU - UKALL14 - Phase 2 Induction |
| 312491000210103 |
LEU - UKALL14 [over 40 years] - Phase 1 Induction |
| 312481000210100 |
LEU ALL - UKALL14 [over 40 years] |
| 312471000210102 |
LYM NHL B-cell - O-CHOP21 [oBINUTUZumab, CYCLOPHOSPHamide, DOXOrubicin, vinCRISTine and prEDNISone] |
| 312461000210108 |
LYM - DA-R-EPOCH LEVEL 6 |
| 312451000210105 |
LYM - DA-R-EPOCH LEVEL 5 |
| 312441000210107 |
LYM - DA-R-EPOCH LEVEL 4 |
| 312431000210104 |
LYM - DA-R-EPOCH LEVEL 3 |
| 312421000210101 |
LYM - DA-R-EPOCH LEVEL 2 |
| 312411000210106 |
LYM - DA-R-EPOCH LEVEL minus 3 |
| 312401000210109 |
LYM - DA-R-EPOCH LEVEL minus 2 |
| 312391000210106 |
LYM - DA-R-EPOCH LEVEL minus 1 |
| 312381000210109 |
LYM - DA-R-EPOCH LEVEL 1 |
| 312371000210107 |
LYM NHL B-cell - DA-R-EPOCH [Dose-adjusted RITUximab, etoposide, prEDNIsone, vinCRISTine, CYCLOPHOSPHamide and DOXOrubicin] [9 levels] |
| 312361000210101 |
LEU - HyperCVAD Part B [60 years and under] Intrathecal CNS prophylaxis High Risk |
| 312351000210104 |
LEU - HyperCVAD Part B [60 years and under] Intrathecal CNS prophylaxis Unknown Risk [default] |
| 312341000210102 |
LEU - HyperCVAD Part A [60 years and under] Intrathecal CNS prophylaxis High Risk |
| 312331000210105 |
LEU - HyperCVAD Part A [60 years and under] Intrathecal CNS prophylaxis Unknown Risk [default] |
| 312321000210108 |
LEU ALL - HyperCVAD Part A and B followed by POMP Maintenance [60 years and under] |
| 312311000210103 |
LEU - HyperCVAD POMP Maintenance |
| 312301000210100 |
LEU - HyperCVAD Part B [over 60 years] Intrathecal CNS prophylaxis High Risk |
| 312291000210104 |
LEU - HyperCVAD Part B [over 60 years] Intrathecal CNS prophylaxis Unknown Risk [default] |
| 312281000210101 |
LEU - HyperCVAD Part A [over 60 years] Intrathecal CNS prophylaxis High Risk |
| 312271000210103 |
LEU - HyperCVAD Part A [over 60 years] Intrathecal CNS prophylaxis Unknown Risk [default] |
| 312261000210109 |
LEU ALL - HyperCVAD Part A and B followed by POMP Maintenance [over 60 years] |
| 312251000210106 |
SAR - VAC [vinCRISTine, daCTINomycin and CYCLOPHOSPHamide][Q2W] |
| 312241000210108 |
SAR Ewing sarcoma - VAC, VC and IE [Q2W] |
| 312231000210100 |
SAR - VAC + VV [vinCRISTine day 1, 8 and 15, daCTINomycin and CYCLOPHOSPHamide] ARST0431 [high risk] |
| 312221000210102 |
SAR - VAC [vinCRISTine, daCTINomycin and CYCLOPHOSPHamide] ARST0431 [high risk] |
| 312211000210107 |
SAR - VDC + V [vinCRISTine days 1 and 8, DOXOrubicin and CYCLOPHOSPHamide] [Q3W] ARST0431 [high risk] |
| 312201000210105 |
SAR - IE [IFOSFamide and etoposide] [Q3W] ARST0431 [high risk] |
| 312191000210108 |
SAR - IE [IFOSFamide and etoposide] [Q2W] ARST0431 [high risk] |
| 312181000210106 |
SAR - VDC + V [vinCRISTine days 1 and 8, DOXOrubicin and CYCLOPHOSPHamide] [Q2W] ARST0431 [high risk] |
| 312171000210109 |
SAR - vinCRISTine days 1 and 8 and irinotecan ARST0431 [high risk] |
| 312161000210103 |
SAR - vinCRISTine days 1, 8 and 15 and irinotecan ARST0431 [high risk] |
| 312151000210101 |
SAR Rhabdomyosarcoma - vinCRISTine, irinotecan, IFOSFamide, etoposide, DOXOrubicin, CYCLOPHOSPHamide and daCTINomycin [ARST0431] [high risk] |
| 312141000210104 |
SAR - VAC [vinCRISTine, daCTINomycin and CYCLOPHOSPHamide][Q3W] |
| 312131000210107 |
SAR Ewing sarcoma - VAC, VC and IE [Q3W] |
| 312121000210105 |
SAR - VC [vinCRISTine and CYCLOPHOSPHamide][Q3W] |
| 312111000210100 |
SAR - IE [IFOSfamide and etoposide][Q3W] |
| 312101000210102 |
SAR - VDC [vinCRISTine, DOXOrubicin and CYCLOPHOSPHamide] [Q3W] |
| 312091000210109 |
SAR Ewing sarcoma - VDC, VC and IE [Q3W] |
| 312081000210107 |
SAR - MA [metHOTREXATe and DOXOrubicin] |
| 312071000210105 |
SAR - MAP [metHOTREXATe, DOXOrubicin and cISplatin] |
| 312061000210104 |
SAR Osteosarcoma - MAP [metHOTREXATe, DOXOrubicin and cISplatin] |
| 312051000210102 |
PCN MM - pamidronate 90mg Q4W |
| 312041000210100 |
LEU ALL precursor B-cell - blinatumomab [CNS1 and CNS2] |
| 312031000210108 |
LEU ALL precursor B-cell - blinatumomab [CNS3] |
| 312021000210106 |
CRC REC Locally advanced - dostarlimab |
| 312011000210101 |
CRC - mFOLFOX6 [low dose foliNIc acid] 9 cycles |
| 312001000210103 |
CRC - mFOLFOX6 [high dose foliNIc acid] 9 cycles |
| 311991000210101 |
CRC - CAPOX 6 cycles |
| 311981000210103 |
CRC REC Neoadjuvant - RAPIDO Total Neoadjuvant Therapy |
| 311971000210100 |
CRC Metastatic - irinotecan [Q3W] dose reduced |
| 311961000210106 |
CRC Metastatic - CETUximab Q2W |
| 311951000210108 |
CRC Metastatic - trifluridine/tipiracil and beVACizumab |
| 311941000210105 |
CRC Metastatic - trifluridine/tipiracil |
| 311931000210102 |
CRC Metastatic - pembrolizumab Q6W [flat dosing] |
| 311921000210104 |
CRC Locally advanced - ipilimumab and nivolumab |
| 311911000210109 |
CRC Metastatic - pembrolizumab Q3W [flat dosing] |
| 311901000210107 |
CRC Metastatic - CETUximab [Q2W] and encorafenib |
| 311891000210106 |
CRC Metastatic - CETUximab [Q2W] and daBRAFEnib |
| 311881000210109 |
LEU - AIDA consolidation 3 [70 years and under] |
| 311871000210107 |
LEU - AIDA consolidation 2 [70 years and under] |
| 311861000210101 |
LEU - AIDA consolidation 1 [70 years and under] |
| 311851000210104 |
LEU - AIDA induction [70 years and under] |
| 311841000210102 |
LEU APL - AIDA induction and consolidations 1, 2 and 3 [70 years and under] |
| 311831000210105 |
LEU - arsenic trioxide and tretinoin consolidation [AML17] |
| 311821000210108 |
LEU - arsenic trioxide and tretinoin induction [AML17] |
| 311811000210103 |
LEU APL - arsenic trioxide and tretinoin induction followed by consolidation [AML17] |
| 311801000210100 |
LEU - APML4 maintenance [61 to 70 years] |
| 311791000210104 |
LEU - APML4 consolidation 2 [61 to 70 years] |
| 311781000210101 |
LEU - APML4 consolidation 1 [61 to 70 years] |
| 311771000210103 |
LEU - APML4 induction [61 to 70 years] |
| 311761000210109 |
LEU APL - APML4 induction, consolidation 1 and 2 followed by maintenance [61 to 70 years] |
| 311751000210106 |
LEU - APML4 maintenance [over 70 years] |
| 311741000210108 |
LEU - APML4 consolidation 2 [over 70 years] |
| 311721000210102 |
LEU - APML4 consolidation 1 [over 70 years] |
| 311711000210107 |
LEU - APML4 induction [over 70 years] |
| 311701000210105 |
LEU APL - APML4 induction, consolidation 1 and 2 followed by maintenance [over 70 years] |
| 311691000210105 |
LEU - Pethema LPA2005 maintenance [70 years and under] [intermediate risk] |
| 311681000210108 |
LEU - Pethema LPA2005 consolidation 3 [70 years and under] [intermediate risk] |
| 311671000210106 |
LEU - Pethema LPA2005 consolidation 2 [70 years and under] [intermediate risk] |
| 311661000210100 |
LEU - Pethema LPA2005 consolidation 1 [70 years and under] [intermediate risk] |
| 311651000210103 |
LEU - Pethema LPA2005 induction [70 years and under] [intermediate risk] |
| 311641000210101 |
LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [70 years and under] [intermediate risk] |
| 311631000210109 |
LEU HCL - cladribine and RITUximab |
| 311621000210107 |
LEU - arsenic trioxide and tretinoin consolidation [standard risk] |
| 311611000210102 |
LEU - arsenic trioxide, tretinoin and prEDNISone induction [standard risk] |
| 311601000210104 |
LEU APL - arsenic trioxide, tretinoin and prEDNISone induction followed by consolidation [standard risk] |
| 311591000210109 |
LEU - APML4 maintenance [60 years and under] |
| 311581000210107 |
LEU - APML4 consolidation 2 [60 years and under] |
| 311571000210105 |
LEU - APML4 consolidation 1 [60 years and under] |
| 311561000210104 |
LEU - APML4 induction [60 years and under] |
| 311551000210102 |
LEU APL - APML4 induction, consolidation 1 and 2 followed by maintenance [60 years and under] |
| 311541000210100 |
LEU - UKALL14 with daSATinib Maintenance |
| 311531000210108 |
LEU - UKALL14 with daSATinib Consolidation [Cycle 4] |
| 311521000210106 |
LEU - UKALL14 with daSATinib consolidation/delayed intensification [Cycle 3] |
| 311511000210101 |
LEU - UKALL14 with daSATinib Consolidation [Cycle 1 and 2] |
| 311501000210103 |
LEU - UKALL14 with daSATinib Intensification/CNS prophylaxis |
| 311491000210108 |
LEU - UKALL14 with daSATinib Phase 2 Induction |
| 311481000210106 |
LEU - UKALL14 with daSATinib Phase 1 Induction |
| 311471000210109 |
LEU ALL precursor B-cell BCR-ABL1+ - UKALL14 with daSATinib |
| 311461000210103 |
LEU - UKALL14 with RITUximab and daSATinib [not for transplant] Maintenance |
| 311451000210101 |
LEU - UKALL14 with RITUximab and daSATinib [not for transplant] Consolidation/delayed intensification [Cycle 3] |
| 311441000210104 |
LEU - UKALL14 with RITUximab and daSATinib [not for transplant] Intensification/CNS prophylaxis |
| 311431000210107 |
LEU - UKALL14 with RITUximab and daSATinib [not for transplant] Phase 2 Induction |
| 311421000210105 |
LEU ALL precursor B-cell BCR-ABL1+ - UKALL14 with RITUximab and daSATinib [not for transplant] |
| 311411000210100 |
LYM - High dose cytarabine [2000mg/m2 TWICE daily days 1 and 2] Consolidation |
| 311401000210102 |
LYM - R-MPV alternating with R-MV |
| 311391000210100 |
LYM NHL B-cell PCNSL - R-MPV [RITUximab, metHOTREXATe, procarbazine and vinCRISTine] followed by high dose cytarabine |
| 311381000210102 |
LYM - EA [etoposide and cytarabine] |
| 311371000210104 |
LYM - MT-R |
| 311361000210105 |
LYM NHL B-cell PCNSL - MT-R [metHOTREXate, temozolomide and RITUximab] followed by EA [etoposide and cytarabine] |
| 311351000210107 |
LYM NHL B-cell Primary Testicular - high dose metHOTREXATe [CNS prophylaxis] |
| 311341000210109 |
LYM NHL B-cell PCNSL - MATRix [metHOTREXATe, cytarabine, thiotepa and RITUximab] Induction |
| 311331000210101 |
LEU CLL Relapsed - aLEMTUzumab [subcut] |
| 311321000210103 |
LEU CLL - venetoclax and oBINUTUZumab |
| 311311000210108 |
LEU CLL - RITUximab and bendamustine |
| 311301000210106 |
LEU CLL Relapsed - aLEMTUzumab [IV] |
| 311291000210107 |
LEU - UKALL14 with RITUximab and daSATinib Consolidation [Cycle 4] |
| 311281000210105 |
LEU - UKALL14 with RITUximab and daSATinib consolidation/delayed intensification [Cycle 3] [for transplant] |
| 311271000210108 |
LEU - UKALL14 with RITUximab and daSATinib Consolidation [Cycle 1 and 2] |
| 311261000210102 |
LEU - UKALL14 with RITUximab and daSATinib [for transplant] Intensification/CNS prophylaxis |
| 311251000210100 |
LEU - UKALL14 with RITUximab and daSATinib Phase 2 Induction [for transplant] |
| 311241000210103 |
LEU - UKALL14 with RITUximab and daSATinib Phase 1 Induction |
| 311231000210106 |
LEU - dexamethasone 6 mg/m2 days 1 to 5 |
| 311221000210109 |
LEU ALL precursor B-cell BCR-ABL1+ - UKALL14 with RITUximab and daSATinib [for transplant] |
| 311211000210104 |
LYM - oBINUTUZumab maintenance |
| 311201000210101 |
LYM - bendamustine and oBINUTUZumab |
| 311191000210103 |
LYM NHL B-cell - bendamustine and oBINUTUZumab |
| 311181000210100 |
LYM NHL NK/T-cell Extra Nodal - DDGP [dexamethasone, cISplatin, gemcitabine and pegaspargase] |
| 311171000210102 |
LEU CLL - venetoclax and RITUximab |
| 311161000210108 |
LEU - imatinib 600 |
| 311151000210105 |
LEU - imatinib 400 |
| 311141000210107 |
LEU CML - imatinib |
| 311131000210104 |
LYM NHL B-cell - Flyer R-CHOP21 [RITUximab, CYCLOPHOSPHamide, DOXOrubicin, vinCRISTine and prEDNISone] followed by RITUximab |
| 311121000210101 |
LEU - UKALL60+ Maintenance |
| 311111000210106 |
LEU - UKALL60+ Consolidation |
| 311101000210109 |
LEU - UKALL60+ Phase 2 Induction |
| 311091000210102 |
LEU - UKALL60+ Phase 1 Induction |
| 311081000210104 |
LEU ALL - UKALL60+ [non-intensive] |
| 311071000210101 |
LEU - UKALL60+ with daSATinib Maintenance |
| 311061000210107 |
LEU - UKALL60+ with daSATinib Consolidation |
| 311051000210109 |
LEU - UKALL60+ with daSATinib Phase 2 Induction |
| 311041000210106 |
LEU - UKALL60+ with daSATinib Phase 1 Induction |
| 311031000210103 |
LEU ALL BCR-ABL1+ - UKALL60+ with daSATinib |
| 311021000210100 |
LEU - UKALL60+ with imatinib Maintenance |
| 311011000210105 |
LEU - UKALL60+ with imatinib Consolidation |
| 311001000210108 |
LEU - UKALL60+ with imatinib Phase 2 Induction |
| 310991000210109 |
LEU - UKALL60+ with imatinib Phase 1 Induction |
| 310981000210107 |
LEU - dexamethasone 6 mg/m2 [max 10 mg] days 1 to 5 |
| 310971000210105 |
LEU ALL BCR-ABL1+ - UKALL60+ with imatinib |
| 310961000210104 |
LEU AML - DA+GO-2 [DAUNOrubicin, cytarabine and Mylotarg [gemtuzumab ozogamicin]] induction [de novo CD33+] [good or intermediate risk] |
| 310951000210102 |
LEU AML - 7 + 3 IDA [IDArubicin and cytarabine] induction |
| 310941000210100 |
LEU - High dose cytarabine [1000mg/m2 TWICE daily days 1 to 6] consolidation |
| 310931000210108 |
LEU - DA[45] 3+7 [DAUNOrubicin and cytarabine] induction [over 60 years] |
| 303631000210108 |
LEU AML - DA[45] 3+7 [DAUNOrubicin and cytarabine] induction followed by high dose cytarabine consolidation [over 60 years] |
| 303621000210106 |
LEU - High dose cytarabine and midostaurin consolidation [under 60 years] |
| 303611000210101 |
LEU - DAUNOrubicin, cytarabine and midostaurin induction [under 60 years] |
| 303601000210103 |
LEU AML - DAUNOrubicin, cytarabine and midostaurin induction, high dose cytarabine and midostaurin consolidation followed by midostaurin maintenance [FLT3 mutated] [under 60 years] |
| 303591000210108 |
LEU - Midostaurin maintenance |
| 303581000210106 |
LEU - High dose cytarabine and midostaurin consolidation [60 years and over] |
| 303571000210109 |
LEU - DAUNOrubicin, cytarabine and midostaurin induction [60 years and over] |
| 303561000210103 |
LEU AML - DAUNOrubicin, cytarabine and midostaurin induction, high dose cytarabine and midostaurin consolidation followed by midostaurin maintenance [FLT3 mutated] [60 years and over] |
| 303551000210101 |
LEU - Manchester Protocol [mitoxantrone and cytarabine IV] consolidation |
| 303541000210104 |
LEU - Manchester Protocol [mitoxantrone and cytarabine IV] induction |
| 303531000210107 |
LEU AML - Manchester Protocol [mitoxantrone and cytarabine IV] induction followed by consolidation |
| 303521000210105 |
LYM NHL B-cell PCNSL Relapsed - R-IE [RITUximab, IFOSFamide and etoposide] |
| 303511000210100 |
LYM - procarbazine [100 mg daily for 5 days] |
| 303501000210102 |
LYM - R-MP [RITUximab, metHOTREXATe, procarbazine] [65 years and over] |
| 303491000210107 |
LYM NHL B-cell PCNSL - R-MP [RITUximab, metHOTREXATe and procarbazine] followed by procarbazine maintenance [65 years and over] |
| 303481000210105 |
LYM NHL B-cell - RITUximab and bendamustine |
| 303471000210108 |
LYM NHL B-cell - RITUximab Maintenance Q8W |
| 303461000210102 |
LYM NHL B-cell - RITUximab Q1W |
| 303451000210100 |
GYN CX Advanced - cISplatin, PACLItaxel, beVACizumab and pembrolizumab |
| 303441000210103 |
GYN CX Advanced - cISplatin, PACLItaxel and pembrolizumab |
| 265711000210103 |
Neuroendocrine carcinoma - cISplatin and etoposide 60/120 chemoradiation |
| 265701000210100 |
Neuroendocrine carcinoma - cISplatin and etoposide 80/100 chemoradiation |
| 265691000210100 |
Desmoid fibromatosis - metHOTREXATe and vinBLASTine |
| 265681000210102 |
SAR STS Metastatic - DOCEtaxel and gemcitabine 900 |
| 265671000210104 |
SAR STS Metastatic - DOCEtaxel and gemcitabine 675 [GeDDis] |
| 265661000210105 |
SAR STS Advanced - trabectedin |
| 265651000210107 |
SAR STS Advanced - pAZOPanib |
| 265641000210109 |
SAR STS Advanced - IFOSFamide [3-day] |
| 265631000210101 |
SAR - VC [vinCRISTine and CYCLOPHOSPHamide][Q2W] |
| 265621000210103 |
SAR - IE [IFOSfamide and etoposide][Q2W] |
| 265611000210108 |
SAR - VDC [vinCRISTine, DOXOrubicin and CYCLOPHOSPHamide] with dexrazoxane [Q2W] |
| 265601000210106 |
SAR Ewing sarcoma - VDC with dexrazoxane, VC and IE [Q2W] |
| 265591000210101 |
SAR STS Advanced - DOXOrubicin and IFOSFamide 25/3000 |
| 265581000210103 |
SAR STS Advanced - DOXOrubicin and IFOSFamide 20/2000 |
| 265571000210100 |
SAR Osteosarcoma Advanced - DOXOrubicin [1-day dosing] and cISplatin |
| 265561000210106 |
SAR Ewing sarcoma Relapsed - CYCLOPHOSPHamide and topotecan |
| 265551000210108 |
SAR Rhabdomyosarcoma Relapsed - VIT [vinCRISTine, irinotecan and temozolomide] |
| 265541000210105 |
SAR Osteosarcoma Advanced - DOXOrubicin [3-day split dosing] and cISplatin |
| 265531000210102 |
LYM NHL B-cell - R-MiniCHOP [RITUximab, CYCLOPHOSPHamide, DOXOrubicin, vinCRISTine and prEDNISone] |
| 265521000210104 |
Neuroendocrine carcinoma Advanced - cARBOplatin and oral etoposide |
| 265411000210105 |
GU Renal cell Metastatic - aXITinib and avelumab [flat dose] |
| 265401000210108 |
GU - nivolumab maintenance Q2W [flat dosing] |
| 265391000210105 |
GU Renal cell Advanced - nivolumab and ipilimumab induction followed by nivolumab maintenance Q2W [flat dosing] |
| 265381000210108 |
GU - nivolumab maintenance Q4W [flat dosing] |
| 265371000210106 |
GU - nivolumab and ipilimumab induction |
| 265361000210100 |
GU Renal cell Advanced - nivolumab and ipilimumab induction followed by nivolumab maintenance Q4W [flat dosing] |
| 265351000210103 |
GU URO Metastatic - PACLItaxel Q1W and pembrolizumab Q3W [flat dosing] |
| 265341000210101 |
GU Renal cell Metastatic - leNVAtinib and everolimus |
| 265331000210109 |
GU Bladder Urothelial - gemcitabine [low dose] chemoradiation |
| 265321000210107 |
GU Bladder Urothelial Neoadjuvant - ddMVAC [metHOTREXATe, DOXOrubicin, vinBLASTine and cISplatin] dose dense |
| 264811000210106 |
LEU - daSATinib 140 |
| 264801000210109 |
LEU - daSATinib 100 |
| 264791000210105 |
LEU CML - daSATinib |
| 264781000210108 |
LEU HCL - cladribine |
| 264771000210106 |
PCN MM - lenalidomide and dexamethasone |
| 264761000210100 |
GYN VUL Advanced - ciSplatin [Q1W] chemoradiation |
| 264751000210103 |
LUNG NSCLC Locally advanced/Metastatic - cARBOplatin and gemcitabine |
| 264741000210101 |
LUNG NSCLC Locally advanced/Metastatic - cARBOplatin and vinORELBine |
| 264731000210109 |
SAR Ewing sarcoma Relapsed - irinotecan and temozolomide |
| 264721000210107 |
Desmoid fibromatosis - metHOTREXATe and vinORELBine |
| 264411000210109 |
LEU CLL - chlorambucil and oBINUTUZumab |
| 264401000210107 |
LEU - nilotinib 300 |
| 264391000210109 |
LEU - nilotinib 400 |
| 264381000210107 |
LEU CML - nilotinib |
| 264371000210105 |
CNS GBM Recurrent - beVACizumab and irinotecan 340 mg/m2 |
| 264361000210104 |
LYM Relapsed - ICE [fractionated IFOSFamide, cARBOplatin and etoposide] |
| 264351000210102 |
LYM NHL B-cell Relapsed - R-ICE [RITUximab, fractionated IFOSFamide, cARBOplatin and etoposide] |
| 264341000210100 |
LYM NHL B-cell MCL - R-BAC [RITUximab, bendamustine and cytarabine] |
| 264331000210108 |
LYM NHL B-cell Lymphoplasmacytic - ibrutinib [Waldenström macroglobulinema] |
| 264321000210106 |
LYM HL Advanced - ChlVPP [chlorambucil, vinBLASTine, procarbazine and prEDNISone] |
| 264011000210104 |
PCN MM Relapsed - pomalidomide, bortezomib and dexamethasone |
| 264001000210101 |
Myelodysplastic syndrome - azacitidine [7 day] |
| 263991000210105 |
Myelodysplastic syndrome - azacitidine [5 day] |
| 263981000210108 |
LEU AML Relapsed - FLAG [fludarabine, cytarabine and filgrastim] [60 years and over] |
| 263971000210106 |
CNS GBM Recurrent - beVACizumab and lomustine |
| 263961000210100 |
CNS GBM Recurrent - beVACizumab Q2W |
| 263951000210103 |
CNS GBM Recurrent - beVACizumab Q3W |
| 263941000210101 |
CNS GLI Recurrent - temozolomide [high grade] |
| 263931000210109 |
CNS - temozolomide following chemoradiation |
| 263921000210107 |
CNS - temozolomide chemoradiation |
| 60091000210105 |
GYN - cARBOplatin and PACLItaxel [following chemoradiation] |
| 60081000210108 |
GYN - cISplatin chemoradiation |
| 60071000210106 |
GYN END Adjuvant - cISplatin chemoradiation followed by cARBOplatin and PACLItaxel |
| 60061000210100 |
GYN OV Recurrent - topotecan |
| 60051000210103 |
GYN END Adjuvant - cARBOplatin and PACLItaxel [chemotherapy-only] |
| 60041000210101 |
GYN VUL Advanced - CARBOplatin [Q1W] chemoradiation |
| 60031000210109 |
GYN OV Recurrent - topotecan and beVACizumab Q4W |
| 60021000210107 |
GYN GTD - TP-TE [PACLItaxel, cISplatin - PACLItaxel and etoposide] [relapsed or high risk] |
| 60011000210102 |
GYN GTD - EP-EMA [etoposide, ciSplatin, etoposide, metHOTREXATe and daCTINomycin] [high risk] |
| 60001000210104 |
GYN OV Low grade serous carcinoma - letrozole maintenance |
| 59991000210107 |
GYN OV Recurrent - CYCLOPHOSPHamide oral [2/4 dosing] |
| 59981000210105 |
GYN OV Recurrent - CYCLOPHOSPHamide oral [continuous] |
| 59971000210108 |
GYN OV Recurrent - etoposide oral |
| 59961000210102 |
GYN OV Recurrent - gemcitabine |
| 59951000210100 |
GYN OV Recurrent - pegylated liposomal DOXOrubicin hydrochloride |
| 59941000210103 |
GYN OV Recurrent - pegylated liposomal DOXOrubicin hydrochloride and beVACizumab |
| 59931000210106 |
GYN CX Locally advanced - cARBOplatin [Q1W] chemoradiation |
| 59921000210109 |
GYN CX Locally advanced - cISplatin [Q1W] chemoradiation |
| 59911000210104 |
GYN GTD - EMA-CO [etoposide, metHOTREXATe, daCTINomycin, CYCLOPHOSPHamide and vinCRISTine] [high risk] |
| 59901000210101 |
LUNG NSCLC Locally advanced - durvalumab Q2W [weight based dosing] |
| 496201000210103 |
Malignancy, direct spread to cervix and/or vagina |
| 496211000210101 |
Cervix specimen from partial hysterectomy |
| 496231000210108 |
Cervix specimen from total hysterectomy |
| 496241000210100 |
Polyp specimen |
| 496191000210100 |
Endocervical adenocarcinoma, superficially invasive |
| 497441000210104 |
SACT regimen type |
| 497451000210101 |
Prescribed dose unit |
| 497461000210103 |
Administered dose unit |
| 495991000210106 |
Tumour width |
| 496001000210105 |
Tumour depth |
| 495981000210109 |
Tumour length |
| 7283002 |
Base of tongue |
| 1340143004 |
Intrahepatic bile duct |
| 505941000210108 |
Extra-adrenal paraganglioma primary |
| 507401000210108 |
Histopathology request |
| 507411000210105 |
Histopathology report |
